Gefitinib-induced Paronychia Teated by Cyosurgery.

Author: Song KIM ¹ ; Ji Ho PARK ; Won Serk KIM ; Joo Heung LEE ; Jun Mo YANG ; Eil Soo LEE
Author Information

1. Department of Dermatology, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea. jmyang@smc.samsung.co.kr
Publication Type:Case Report
Keywords: Cryosurgery; Gefitinib; Paronychia
MeSH: Activities of Daily Living; Carcinoma, Non-Small-Cell Lung; Cryosurgery; Paronychia*; Receptor, Epidermal Growth Factor
From:Annals of Dermatology 2007;19(4):173-175
CountryRepublic of Korea
Language:English
Abstract: Gefitinib (Iressa, ZD1839) is one of the epidermal growth factor receptor (EGFR) inhibitors approved for the treatment of advanced non-small cell lung cancer. The cutaneous reactions to EGFR inhibitors manifest as a follicular eruption, nail toxicity, xerosis, or desquamation. These adverse events, if not properly managed, can interfere with activities of daily living. We report a case of paronychia induced by gefitinib successfully treated with cryosurgery which is a simple and safe treatment.